Abigail Neiman, MD
Rheumatology · Houston, TXNPI 1043280381
Payments from drug & device makers
Across 598 payments — averaging $2884.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$554K
- AbbVie$381K
- Pfizer$240K
- Novartis$163K
- Regeneron$151K
- Eli Lilly$77K
- plus $160K from 30 others
Across 3 payments — averaging $16,113 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$48K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 62 | $553,587 |
| AbbVie | 204 | $380,885 |
| Pfizer | 44 | $240,415 |
| Novartis | 30 | $162,661 |
| Regeneron | 33 | $150,682 |
| Eli Lilly | 16 | $76,715 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $76,228 |
| Radius Health, Inc. | 56 | $47,058 |
| E.r. Squibb & Sons, L.L.C. | 5 | $21,374 |
| Dr.reddy's Laboratories,inc. | 9 | $12,761 |
| GSK | 14 | $387 |
| UCB, Inc. | 15 | $361 |
| Johnson & Johnson(2 entities) | 16 | $327 |
| AstraZeneca(2 entities) | 10 | $212 |
| Boehringer Ingelheim | 4 | $203 |
| Sanofi | 10 | $174 |
| Organon | 14 | $164 |
| Mallinckrodt Hospital Products Inc. | 7 | $133 |
| Genentech USA, Inc. | 2 | $131 |
| Mallinckrodt Enterprises LLC | 7 | $120 |
| Aurinia Pharma U.S., Inc. | 3 | $106 |
| Alvogen Inc | 4 | $81 |
| Janssen Scientific Affairs, LLC | 2 | $79 |
| Fresenius Kabi USA, LLC | 2 | $51 |
| Hikma Pharmaceuticals USA | 2 | $45 |
| Sandoz | 2 | $43 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $38 |
| ANI Pharmaceuticals, Inc. | 2 | $36 |
| Fidia Pharma USA Inc. | 1 | $25 |
| Celltrion USA Inc. | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Sobi, Inc | 1 | $19 |
| Sanofi-aventis U.S. LLC | 2 | $19 |
| Medtronic | 1 | $15 |
| Mylan Institutional Inc. | 1 | $15 |
| Merck | 1 | $13 |
How this compares
$1,725,197 in reported general payments places this provider in the 95th percentile of 512 rheumatology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Houston
- Philip WallerHouston$4.9M
- Qaiser RehmanHouston$2.3M
- Michelle EisenbergHouston$1.8M
- Maureen MayesHouston$1.6M
- Wajeeha YousafHouston$1.3M
- Laila HassanHouston$870K
- Shervin AssassiHouston$667K
- Jacqueline VoHouston$520K
- Naureen AlimHouston$397K
- Paul PickrellAustin$40.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.